Page last updated: 2024-11-12
notoamide b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
notoamide B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16127923 |
| CHEMBL ID | 2042022 |
| MeSH ID | M0510811 |
Synonyms (6)
| Synonym |
|---|
| (-)-notoamide b |
| CHEMBL2042022 |
| notoamide b |
| (1's,3r,7's,9's)-7,7,10',10'-tetramethylspiro[1h-pyrano[2,3-g]indole-3,11'-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2,2',14'-trione |
| 937791-52-1 |
| DTXSID801046203 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (14)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID667073 | Antifungal activity against Candida albicans DAY185 assessed as inhibition of biofilm formation after 48 hrs by XTT assay | 2012 | Journal of natural products, Apr-27, Volume: 75, Issue:4 | Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans. |
| AID735803 | Cytotoxicity against human HL60 cells assessed as inhibition of cell viability by MTT assay | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID1634821 | Activation of Escherichia coli BLR (DE3) ClpP using bovine milk FITC-beta casein as substrate assessed as change in relative fluorescent units at 50 uM preincubated for 15 mins followed by substrate addition measured every 30 mins for 6 hrs by fluorescenc | 2016 | Journal of natural products, Apr-22, Volume: 79, Issue:4 | Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease P. |
| AID735808 | Antibacterial activity against Vibrio anguillarum ATCC 19019 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID735809 | Antibacterial activity against Escherichia coli ATCC 25922 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID735813 | Antibacterial activity against Bacillus cereus ACCC 11077 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID735811 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID735807 | Antibacterial activity against Vibrio parahaemolyticus ATCC 17802 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID735806 | Antibacterial activity against Pseudomonas putida ATCC 17848 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID1465315 | Inhibition of RANKL-induced formation of multinuclear osteoclasts in mouse RAW264 cells at 10 ug/ml after 4 days by p-NPP substrate based absorbance method | 2017 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22 | Enantioselective inhibitory abilities of enantiomers of notoamides against RANKL-induced formation of multinuclear osteoclasts. |
| AID735810 | Antibacterial activity against Staphylococcus aureus ATCC 27154 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID667072 | Antifungal activity against Candida albicans DAY185 assessed as lowest compound concentration causing =>80% reduction in cell viability after 48 hrs by XTT assay | 2012 | Journal of natural products, Apr-27, Volume: 75, Issue:4 | Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans. |
| AID735812 | Antibacterial activity against Micrococcus tetragenus ATCC 13623 assessed as growth inhibition | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| AID735804 | Cytotoxicity against human K562 cells assessed as inhibition of cell viability by MTT assay | 2013 | Journal of natural products, Apr-26, Volume: 76, Issue:4 | Bioactive indole alkaloids and phenyl ether derivatives from a marine-derived Aspergillus sp. Fungus. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.12) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||